title: New preclinical guidelines on drug effects on ventricular repolarization: safety pharmacology comes of age.
authors.affiliation: Safety Assessment U.S., Development, AstraZeneca Pharmaceuticals, Wilmington, DE 19850-5437, USA. lewis.kinter@astrazeneca.com
authors.forename: Lewis B
authors.initials: LB
authors.lastname: Kinter
authors.forename: Peter K S
authors.initials: PK
authors.lastname: Siegl
authors.forename: Alan S
authors.initials: AS
authors.lastname: Bass
mesh_terms: D000818:Animals; D015415:Biomarkers; D004353:Drug Evaluation, Preclinical / Q000592:standards*; D004562:Electrocardiography / Q000187:drug effects*; D017408:Guidelines as Topic; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced*; D018570:Risk Assessment; D012449:Safety / Q000592:standards; D016276:Ventricular Function
chemical_list: D015415:Biomarkers